Literature DB >> 29622656

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Paolo Strati1, Dai Chihara2, Yasuhiro Oki3, Luis E Fayad3, Nathan Fowler3, Loretta Nastoupil3, Jorge E Romaguera3, Felipe Samaniego3, Naveen Garg4, Lei Feng5, Emily T Wesson3, Charnelle E Ruben3, Mildred D Stafford3, Yago Nieto6, Issa F Khouri6, Chitra Hosing6, Sandra B Horowitz3, Rammurti T- Kamble7, Michelle A Fanale8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29622656      PMCID： PMC6119133          DOI： 10.3324/haematol.2018.187617

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Authors:  M Loirat; P Chevallier; C Leux; A Moreau; C Bossard; T Guillaume; T Gastinne; J Delaunay; N Blin; B Mahé; V Dubruille; K Augeul-Meunier; P Peterlin; H Maisonneuve; P Moreau; N Juge-Morineau; H Jardel; M Mohty; P Moreau; S Le Gouill
Journal:  Ann Oncol       Date:  2014-11-12       Impact factor: 32.976

2.  Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

Authors:  Jehan Dupuis; Franck Morschhauser; Hervé Ghesquières; Hervé Tilly; Olivier Casasnovas; Catherine Thieblemont; Vincent Ribrag; Céline Bossard; Fabien Le Bras; Emmanuel Bachy; Bénédicte Hivert; Emmanuelle Nicolas-Virelizier; Fabrice Jardin; Jean-Noel Bastie; Sandy Amorim; Julien Lazarovici; Antoine Martin; Bertrand Coiffier
Journal:  Lancet Haematol       Date:  2015-03-17       Impact factor: 18.959

Review 3.  Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.

Authors:  A D Zelenetz; P Hamlin; T Kewalramani; J Yahalom; S Nimer; C H Moskowitz
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

4.  Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.

Authors:  M S Hertzberg; C Crombie; W Benson; J Taper; D Gottlieb; K F Bradstock
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

5.  DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.

Authors:  Jan-Henrik Mikesch; Mareike Kuhlmann; Angela Demant; Utz Krug; Gabriela B Thoennissen; Eva Schmidt; Torsten Kessler; Christoph Schliemann; Michele Pohlen; Michael Mohr; Georg Evers; Gabriele Köhler; Johannes Wessling; Rolf Mesters; Carsten Müller-Tidow; Wolfgang E Berdel; Nils H Thoennissen
Journal:  Ann Hematol       Date:  2013-03-27       Impact factor: 3.673

6.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors:  Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

7.  Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.

Authors:  E Jantunen; T Wiklund; E Juvonen; M Putkonen; T Lehtinen; O Kuittinen; K Franssila; K-O Söderström; S Leppä; E Elonen; K Remes; T Nousiainen
Journal:  Bone Marrow Transplant       Date:  2004-02       Impact factor: 5.483

8.  Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.

Authors:  Sonali M Smith; Linda J Burns; Koen van Besien; Jennifer Lerademacher; Wensheng He; Timothy S Fenske; Ritsuro Suzuki; Jack W Hsu; Harry C Schouten; Gregory A Hale; Leona A Holmberg; Anna Sureda; Cesar O Freytes; Richard Thomas Maziarz; David J Inwards; Robert Peter Gale; Thomas G Gross; Mitchell S Cairo; Luciano J Costa; Hillard M Lazarus; Peter H Wiernik; Dipnarine Maharaj; Ginna G Laport; Silvia Montoto; Parameswaran N Hari
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

Authors:  Paolo Corradini; Anna Dodero; Francesco Zallio; Daniele Caracciolo; Marco Casini; Marco Bregni; Franco Narni; Francesca Patriarca; Mario Boccadoro; Fabio Benedetti; A Rambaldi; Alessandro M Gianni; Corrado Tarella
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Authors:  Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan Iyer; Andrei Shustov; Tina Nielsen; Jean Nichols; Julie Wolfson; Barbara Balser; Steven Horwitz
Journal:  J Hematol Oncol       Date:  2014-01-23       Impact factor: 17.388
View more
  9 in total

Review 1.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 2.  Peripheral T-Cell Lymphomas: Therapeutic Approaches.

Authors:  David Sibon
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

Review 3.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

4.  Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

Authors:  Zachary D Epstein-Peterson; Steven M Horwitz
Journal:  Semin Hematol       Date:  2021-03-03       Impact factor: 3.851

Review 5.  Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.

Authors:  Tengrui Zhang; Yueqing Gong; Hui Meng; Chen Li; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2020-05-24       Impact factor: 6.551

Review 6.  Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.

Authors:  Donglu Wu; Ye Qiu; Yunshuang Jiao; Zhidong Qiu; Da Liu
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

Review 7.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388

8.  Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Authors:  Cesar Gentille; Humaira Sarfraz; Jitesh Joshi; Jasleen Randhawa; Shilpan Shah; Sai Ravi Pingali
Journal:  Cancer Rep (Hoboken)       Date:  2022-03-08

9.  Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.

Authors:  Tricia Tay; Nagavalli Somasundaram; Cindy Lim; Lay Poh Khoo; Allan Zhi Kai Goh; Yuh Shan Lee; Xin Liu; Miriam Tao; Richard Quek; Mohamad Farid; Eileen Poon; Jason Y S Chan; Esther W Y Chang; Valerie S W Yang; Yeow Tee Goh; Daryl Tan; Colin Diong; Nicholas F Grigoropoulos; Chandramouli Nagarajan; Michelle Poon; Sanjay de Mel; Anand Jeyasekharan; Esther H L Chan; Joanne Lee; Yen Lin Chee; Soon Thye Lim; Tiffany Tang
Journal:  Cancer Rep (Hoboken)       Date:  2022-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.